SGLT2 Inhibitor Empagliflozin Safe and Effective for Heart Attack Patients
Empagliflozin was found to be safe and reduce heart failure events for heart attack patients and can be initiated shortly after hospitalization without risk to kidney function, even in patients with chronic kidney disease.